18+ · Research use only
Tirzepatide 15mg, Philippines
Peptide studied in Phase 3 human trials. Lyophilized powder, stocked in Metro Manila. For laboratory research use only.
What it did in trials
- 20.9% avg weight loss, Phase 3
- Diabetes: 14.7% avg loss, Phase 3
Choose a pack
Pack price replaces the 10% off. One compound per pack.
Pack price replaces the standing 10% off; they don't stack. One compound per pack.
Check out once for the whole cart. Pay by QR, confirm on WhatsApp.
Add more compounds if you like, then check out once. You pay by QR on your order page and send the screenshot on WhatsApp.
In the Philippines
GCash · Maya · QR Ph bank transfer · InstaPay
From abroad
- International transfer
Wise · International bank transfer · Zelle · Crypto
Payment details are sent in the WhatsApp chat once your order is confirmed.
Order by 12 noon on a weekday for same-day Metro Manila
Includes water, syringes, pads · plain box
60-day money-back guaranteeTerms
Order by 12 noon on a weekday for same-day delivery in Metro Manila
Metro Manila rider ₱150 · Luzon 1-2 days · Visayas 2-3 days · Mindanao 3-5 days
Everything to reconstitute is included
5 x 3ml water · 50 syringes · 50 pads · plain outer packaging
60-day money-back guarantee
If an accredited independent laboratory reports that this vial is not the compound on the label, we refund what you paid for it. Evidence within 60 calendar days of delivery; you do not send anything back. Terms
Updated 12 October 2026
- Human evidence
- Phase 3
- Manufacturing
- cGMP · ISO 9001 · ISO 13485
- Latest batch report
- Report pending
- Storage
- 2 to 8 °C sealed
Tirzepatide in the Philippines
Tirzepatide is a dual agonist of the GLP-1 and GIP receptors, the compound behind the Mounjaro and Zepbound brands. In the SURMOUNT-1 trial it produced 22.5% mean weight reduction over 72 weeks, and it remains the benchmark against which newer incretin compounds are measured.
Primara Labs stocks tirzepatide as a 15mg lyophilized vial at ₱2,100, or ₱1,890 with the standing 10% off. Local suppliers generally list tirzepatide in vials from 15mg up to 60mg, so this is the same presentation most of the market sells, at a lower total. Vials are in stock, dispatching same day across Metro Manila on orders verified before noon.
Tirzepatide acts at two receptors, GLP-1 and GIP. Retatrutide adds a third, the glucagon receptor, and sits one stage behind in development: tirzepatide is an approved medicine in several markets under its brand names, while retatrutide is in Phase 3 and approved nowhere. Both are held in the same Metro Manila cold storage for buyers who buy retatrutide Philippines stock alongside this vial.
Tirzepatide ships as a freeze-dried 15mg vial. Keep it sealed and refrigerated until the day it is used in the lab. Ordering takes one message: the WhatsApp button fills in the product and pack, and we answer with the total and the delivery time. Ordered before 12 noon on a weekday, Metro Manila addresses receive the same day. Provincial parcels reach Luzon in 1 to 2 business days, the Visayas in 2 to 3 and Mindanao in 3 to 5. How the compound was developed and studied is covered in the Tirzepatide guide.
Deeper read: Tirzepatide in the Philippines: vial pricing
Regulatory status
Tirzepatide. FDA Philippines: not established. US FDA: Approved for glycemic control in type 2 diabetes mellitus (Mounjaro); weight reduction in obesity or overweight with a comorbidity and moderate to severe obstructive sleep apnea in adults with obesity (Zepbound). Checked 23 September 2026.
Sold for laboratory research only, not for human consumption. Primara Labs does not give medical advice or dosing guidance. Regulatory Status Tracker
Laboratory handling
Reconstitution reference
| BAC water added | Resulting concentration | Note |
|---|---|---|
| 1.0 ml | 15 mg/ml | Highest concentration |
| 2.0 ml | 7.5 mg/ml | Common reference dilution |
| 3.0 ml | 5 mg/ml | Larger volumes, finer graduation |
Reconstitute with bacteriostatic water. Reference values are for laboratory preparation only. Other volumes: reconstitution calculator, prefilled for Tirzepatide 15mg.
Handling and storage
Sealed vials
Store sealed lyophilised vials refrigerated at 2 to 8 °C, away from light.
Primara Labs storage instructionAdding diluent
Add the diluent slowly down the inside wall of the vial rather than straight onto the powder.
Mixing
The US prescribing instructions for tesamorelin, a lyophilised peptide medicine, tell users to swirl the vial to mix the powder and liquid, and not to shake it.
Tesamorelin US instructions for use, DailyMed · checked 23 September 2026Appearance
The same instructions say not to use the solution if it is cloudy, discoloured or has particles in it.
Tesamorelin US instructions for use, DailyMed · checked 23 September 2026After the stopper is punctured
CDC guidance, citing USP chapter 797, is that a multi-dose vial once opened is dated and discarded within 28 days unless the manufacturer states another date, and never used past its original expiry.
CDC, Preventing Unsafe Injection Practices · checked 23 September 2026What it did in trials
Sources for the trial highlights
- 1.SURMOUNT-1, 2022. Adults with BMI of 30 or more, or 27 or more with at least one weight-related complication, excluding diabetes.
- 2.SURMOUNT-2, 2023. Adults (18 or older) with BMI of 27 kg/m2 or higher and type 2 diabetes with HbA1c 7-10% (53-86 mmol/mol), in seven countries.
Benefits studied
Body-weight reduction
Phase 3 humanIn SURMOUNT-1, a phase 3 trial in adults with BMI of 30 or more, or 27 or more with at least one weight-related complication, excluding diabetes (n=2,539), mean body weight fell 20.9% on the 15 mg arm over 72 weeks, against 3.1% lost on placebo (treatment-regimen estimand).
Jastreboff AM et al. N Engl J Med 2022;387:205-216 · checked 23 September 2026Body-weight reduction with type 2 diabetes
Phase 3 humanIn SURMOUNT-2, a phase 3 trial in adults (18 or older) with BMI of 27 kg/m2 or higher and type 2 diabetes with HbA1c 7-10% (53-86 mmol/mol), in seven countries (n=938), mean body weight fell 14.7% on the 15 mg arm over 72 weeks, against 3.2% lost on placebo (treatment-regimen estimand).
Garvey WT et al. Lancet 2023 (SURMOUNT-2) · checked 23 September 2026Maintenance of weight reduction
Phase 3 humanIn SURMOUNT-4, a phase 3 withdrawal trial (n=670), participants who continued tirzepatide after a 36-week lead-in lost a further 5.5% by week 88, while those switched to placebo regained 14.0%.
Aronne LJ et al. JAMA 2024 (SURMOUNT-4) · checked 23 September 2026Body-weight reduction against semaglutide
Phase 3 humanIn SURMOUNT-5, a phase 3b head-to-head trial in adults with obesity but without type 2 diabetes (n=751), mean body weight fell 20.2% on tirzepatide against 13.7% on semaglutide over 72 weeks.
Aronne LJ et al. N Engl J Med 2025 (SURMOUNT-5) · checked 23 September 2026
Side effects reported
In SURMOUNT-1, discontinuation because of adverse events was 4.3% on 5 mg, 7.1% on 10 mg and 6.2% on 15 mg, against 2.6% on placebo.
Jastreboff AM et al. N Engl J Med 2022;387:205-216 · checked 23 September 2026In SURMOUNT-3, discontinuation because of adverse events was 10.5% on maximum tolerated dose (10 or 15 mg), against 2.1% on placebo. The most frequently reported adverse events were nausea in 39.7% on maximum tolerated dose (10 or 15 mg) against 14.0% on placebo, diarrhoea in 31.0% on maximum tolerated dose (10 or 15 mg) against 9.2% on placebo, constipation in 23.0% on maximum tolerated dose (10 or 15 mg) against 6.8% on placebo and vomiting in 18.1% on maximum tolerated dose (10 or 15 mg) against 1.4% on placebo.
Wadden TA et al. Nat Med 2023 (SURMOUNT-3) · checked 23 September 2026Findings are described as the research reported them, with the level of evidence for each. They are not a claim about any vial sold here, which is supplied for laboratory research use only.
How it works
Tirzepatide is a single peptide that activates two receptors: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1.
Targets: GIP and GLP-1 receptors
What the research shows
Tirzepatide has five completed phase 3 obesity trials in the Research Desk dataset, SURMOUNT-1 to SURMOUNT-5, published between 2022 and 2025. SURMOUNT-5 compared it head to head with semaglutide in adults with obesity without type 2 diabetes. Its wider trial record, including its diabetes programme, is larger than this dataset holds.
Phase 3 · 72 weeks
SURMOUNT-1In SURMOUNT-1, a phase 3 trial of tirzepatide in adults with BMI of 30 or more, or 27 or more with at least one weight-related complication, excluding diabetes (n=2,539), mean body weight fell 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg over 72 weeks, against 3.1% on placebo (treatment-regimen estimand; Jastreboff AM et al. N Engl J Med 2022;387:205-216).
In SURMOUNT-1, discontinuation because of adverse events was 4.3% on 5 mg, 7.1% on 10 mg and 6.2% on 15 mg, against 2.6% on placebo.
Phase 3 · 72 weeks
SURMOUNT-2In SURMOUNT-2, a phase 3 trial of tirzepatide in adults (18 or older) with BMI of 27 kg/m2 or higher and type 2 diabetes with HbA1c 7-10% (53-86 mmol/mol), in seven countries (n=938), mean body weight fell 12.8% on 10 mg and 14.7% on 15 mg over 72 weeks, against 3.2% on placebo (treatment-regimen estimand; Garvey WT et al. Lancet 2023 (SURMOUNT-2)).
SURMOUNT-2: The abstract reports that few adverse events led to discontinuation (under 5%) without per-arm figures.
Phase 3 · 72 weeks
SURMOUNT-3In SURMOUNT-3, a phase 3 trial of tirzepatide in adults with BMI of 30 or more, or 27 or more with at least one obesity-related complication (excluding diabetes), who achieved 5.0% or more weight reduction after a 12-week intensive lifestyle intervention (n=579), mean body weight changed by -18.4% on maximum tolerated dose (10 or 15 mg) over 72 weeks, against +2.5% on placebo (treatment-regimen estimand; Wadden TA et al. Nat Med 2023 (SURMOUNT-3)).
In SURMOUNT-3, discontinuation because of adverse events was 10.5% on maximum tolerated dose (10 or 15 mg), against 2.1% on placebo. The most frequently reported adverse events were nausea in 39.7% on maximum tolerated dose (10 or 15 mg) against 14.0% on placebo, diarrhoea in 31.0% on maximum tolerated dose (10 or 15 mg) against 9.2% on placebo, constipation in 23.0% on maximum tolerated dose (10 or 15 mg) against 6.8% on placebo and vomiting in 18.1% on maximum tolerated dose (10 or 15 mg) against 1.4% on placebo.
Phase 3 · 88 weeks
SURMOUNT-4In SURMOUNT-4, a phase 3 trial of tirzepatide in adults with BMI of 30 or more, or 27 or more with a weight-related complication, excluding diabetes (n=670), mean body weight changed by -5.5% on continued tirzepatide, weeks 36 to 88 over 88 weeks, against +14.0% on switched to placebo (treatment-regimen estimand; Aronne LJ et al. JAMA 2024 (SURMOUNT-4)).
In SURMOUNT-4, discontinuation because of adverse events was 1.8% on continued tirzepatide, weeks 36 to 88, against 0.9% on switched to placebo. The most frequently reported adverse events were diarrhoea in 10.7% on continued tirzepatide, weeks 36 to 88 against 4.8% on switched to placebo, nausea in 8.1% on continued tirzepatide, weeks 36 to 88 against 2.7% on switched to placebo and vomiting in 5.7% on continued tirzepatide, weeks 36 to 88 against 1.2% on switched to placebo.
Phase 3b · 72 weeks
SURMOUNT-5In SURMOUNT-5, a phase 3b trial of tirzepatide in adults with obesity but without type 2 diabetes (n=751), mean body weight fell 20.2% on tirzepatide, maximum tolerated dose over 72 weeks, against 13.7% on semaglutide, maximum tolerated dose (Aronne LJ et al. N Engl J Med 2025 (SURMOUNT-5)).
SURMOUNT-5: The abstract does not name the estimand or give adverse event rates.
The first published batch report is retatrutide 20mg batch RETA-4728-A, Janoshik-tested for bacterial endotoxin (key H2KI86I8GWB4), at primaralabs.com/coa. Reports for further compounds are published there per batch as they are issued.
- Type
- Peptide dual incretin receptor agonist
- Molecular formula
- C225H348N48O68
- Molecular weight
- 4,813 g/mol
- CAS
- 2023788-19-2
- PubChem
- CID 166567236
- Presentation
- Lyophilized powder, 15 mg / vial
- Vial size
- 15mg
- Catalogue code
- PRM-006
Frequently asked
Tirzepatide questions, answered
How much is Tirzepatide in the Philippines?
At Primara Labs, Tirzepatide 15mg is ₱1,890 for a single vial, ₱1,470 per vial in a 5 pack (₱7,350 total) and ₱1,155 per vial in a 10 pack (₱11,550 total). Prices are in pesos and the pack price is shown on the product page before you order.
Where can I buy Tirzepatide in the Philippines?
Primara Labs keeps Tirzepatide 15mg in stock in Metro Manila cold storage. Order on WhatsApp from the product page: the message is typed for you, and stock, the total and delivery are confirmed in the chat. There is no on-site checkout.
Do you deliver Tirzepatide to Cebu, Davao and the provinces?
Yes. Metro Manila: same day before 12 noon, Grab Express / Lalamove, ₱150; Luzon: 1 to 2 business days, J&T Express, ₱250; Visayas: 2 to 3 business days, J&T Express, ₱250; Mindanao: 3 to 5 business days, J&T Express, ₱300. Cebu is in the Visayas and Davao in Mindanao. Courier is free on orders over ₱10,000 anywhere in the Philippines. Below that, a Metro Manila rider is ₱150, J&T Express is ₱250 to Luzon and the Visayas and ₱300 to Mindanao.
Is Tirzepatide FDA approved in the Philippines?
Tirzepatide. FDA Philippines: not established. US FDA: Approved for glycemic control in type 2 diabetes mellitus (Mounjaro); weight reduction in obesity or overweight with a comorbidity and moderate to severe obstructive sleep apnea in adults with obesity (Zepbound). Checked 23 September 2026. Primara Labs supplies it for research use only; it is not for human consumption.
Is tirzepatide currently in stock?
It is in stock. Verified orders placed before noon dispatch the same day across Metro Manila, with courier delivery reaching Luzon in 1 to 2 business days, the Visayas in 2 to 3 and Mindanao in 3 to 5.
How does tirzepatide differ from retatrutide in research?
Tirzepatide activates GLP-1 and GIP receptors. Retatrutide adds glucagon receptor activity as a third mechanism and produced larger weight reduction in its Phase 2 trial, though tirzepatide has the longer publication record.
How is tirzepatide delivered?
Vials dispatch from Metro Manila cold storage as sealed, freeze-dried vials in plain outer packaging. Same-day delivery covers Metro Manila on verified orders placed before noon, and provincial couriers reach Luzon in 1 to 2 business days, the Visayas in 2 to 3 and Mindanao in 3 to 5.
What is Tirzepatide studied for?
Tirzepatide has five completed phase 3 obesity trials in the Research Desk dataset, SURMOUNT-1 to SURMOUNT-5, published between 2022 and 2025. SURMOUNT-5 compared it head to head with semaglutide in adults with obesity without type 2 diabetes. Its wider trial record, including its diabetes programme, is larger than this dataset holds.
What side effects were reported for Tirzepatide?
In SURMOUNT-1, discontinuation because of adverse events was 4.3% on 5 mg, 7.1% on 10 mg and 6.2% on 15 mg, against 2.6% on placebo. In SURMOUNT-3, discontinuation because of adverse events was 10.5% on maximum tolerated dose (10 or 15 mg), against 2.1% on placebo. The most frequently reported adverse events were nausea in 39.7% on maximum tolerated dose (10 or 15 mg) against 14.0% on placebo, diarrhoea in 31.0% on maximum tolerated dose (10 or 15 mg) against 9.2% on placebo, constipation in 23.0% on maximum tolerated dose (10 or 15 mg) against 6.8% on placebo and vomiting in 18.1% on maximum tolerated dose (10 or 15 mg) against 1.4% on placebo.
How should Tirzepatide be stored?
Store sealed lyophilised vials refrigerated at 2 to 8 °C, away from light. CDC guidance, citing USP chapter 797, is that a multi-dose vial once opened is dated and discarded within 28 days unless the manufacturer states another date, and never used past its original expiry.
Does Primara Labs publish lab reports for Tirzepatide?
The first published batch report is retatrutide 20mg batch RETA-4728-A, Janoshik-tested for bacterial endotoxin (key H2KI86I8GWB4), at primaralabs.com/coa. Reports for further compounds are published there per batch as they are issued.
Related compounds
Answers
Questions about Tirzepatide, answered
All compounds supplied by Primara Labs are for laboratory research use only and are not for human consumption, diagnostic or therapeutic use. Statements on this page describe published research and have not been evaluated by the Philippine FDA. See Research Use Only terms.